Clene, Inc. (CLNN)

NASDAQ: CLNN · IEX Real-Time Price · USD
3.45
0.00 (0.00%)
At close: Aug 11, 2022 4:00 PM
3.53
+0.08 (2.32%)
Pre-market: Aug 12, 2022 8:02 AM EDT
0.00%
Market Cap 218.23M
Revenue (ttm) 540,000
Net Income (ttm) 16.66M
Shares Out 63.26M
EPS (ttm) 0.28
PE Ratio 12.32
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 179,812
Open 3.52
Previous Close 3.45
Day's Range 3.35 - 3.55
52-Week Range 1.93 - 9.06
Beta 0.42
Analysts Buy
Price Target 15.01 (+335.1%)
Earnings Date Aug 8, 2022

About CLNN

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites... [Read more...]

Industry Biotechnology
Founded 2012
Employees 95
Stock Exchange NASDAQ
Ticker Symbol CLNN
Full Company Profile

Financial Performance

In 2021, Clene's revenue was $723,000, an increase of 250.97% compared to the previous year's $206,000. Losses were -$9.74 million, -49.47% less than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CLNN stock is "Buy." The 12-month stock price forecast is 15.01, which is an increase of 335.07% from the latest price.

Price Target
$15.01
(335.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Will Clene Inc. (CLNN) Report Negative Q2 Earnings? What You Should Know

Clene Inc. (CLNN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS

SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceut...

Why Shares of Clene Jumped 11.8% on Monday

The company's lead therapy has shown progress against ALS in preliminary trials.

HC Wainwright Initiates Coverage On This Nanocrystals Stock

H.C. Wainwright initiated coverage on Clene Inc (NASDAQ: CLNN) with a Buy rating and a $16 price target.  Clene is focused on the development of novel clean-surfaced nanotechnologies consisting of trans...

Why Is Clene (CLNN) Stock Soaring 23% Today?

Clene (CLNN) stock is heading higher on Thursday following the release of data from a long-term clinical trial of CNM-Au8. The post Why Is Clene (CLNN) Stock Soaring 23% Today?

Clene's CNM-Au8 Shows Decreased Mortality Amyotrophic Lateral Sclerosis Patients

Clene Inc (NASDAQ: CLNN) reported significantly improved survival in Amyotrophic lateral sclerosis (ALS) patients initially treated with CNM-Au8 compared to initially randomized placebo-treated particip...

Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

SALT LAKE CITY, July 14, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceut...

Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on Ju...

SALT LAKE CITY, June 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutic...

Why Clene Shares Are Rising

Clene Inc. (NASDAQ: CLNN) shares are trading higher by 10.81% at $2.46 after the company received a $3 million loan from the Maryland Board of Public Works to support production for its lead drug candid...

Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility

$3 million 60-month loan to support capital equipment purchases in new 75,000-square-foot facility in Elkton, Maryland, for manufacture of Clene's lead drug candidate, CNM-Au8®, for treatment of ALS

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

Clene Inc. (CLNN) delivered earnings and revenue surprises of -16.67% and 76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights

SALT LAKE CITY, May 09, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceuti...

Updated Interim Data from Clene Nanomedicine's RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Scie...

Results show significant survival benefit in participants who entered open-label extension of study of CNM-Au8®, a gold nanocrystal suspension, compared to validated ENCALS prediction mode Results show ...

Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights

SALT LAKE CITY, March 11, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutic...

Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022

SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutic...

Clene Nanomedicine to Present Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2022

SALT LAKE CITY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutic...

Clene Nanomedicine Provides Clinical Program Update

SALT LAKE CITY, Feb. 14, 2022 (GLOBE NEWSWIRE) --  Clene Inc. (NASDAQ: CLNN) along with its wholly owned subsidiary Clene Nanomedicine, Inc. (Clene) is a clinical-stage biopharmaceutical company focused...

Clene Nanomedicine's Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial

SALT LAKE CITY, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutic...

Clene Nanomedicine's Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validate...

Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022

Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS...

SALT LAKE CITY, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutic...

Clene Nanomedicine's RESCUE-ALS Phase 2 Results Selected for Late-Breaking Presentation at 32nd International Symposi...

SALT LAKE CITY, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutic...

Clene Inc. (CLNN) Upgraded to Buy: What Does It Mean for the Stock?

Clene Inc. (CLNN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Clene Inc. (CLNN) Could Rally 288%: Here's is How to Trade

The consensus price target hints at a 287.8% upside potential for Clene Inc. (CLNN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat...

Clene's Amyotrophic Lateral Sclerosis Candidate Shows Favorable Impact On Disease Progression

Clene Inc (NASDAQ: CLNN) presented new data from the RESCUE-ALS Phase 2 study of CNM-Au8, a catalytically active gold nanocrystal suspension for amyotrophic lateral sclerosis (ALS). Data were shared at ...

Does Clene Inc. (CLNN) Have the Potential to Rally 238% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Clene Inc. (CLNN). While the effectiveness of this highly sought-after metric is questionable, the posi...